CAR T Cell Related Neurotoxicity- Enduring
In 2018 it was estimated that approximately 609,640 people would die from some form of cancer. Chimeric Antigen Receptor T cell therapy is a very promising field in the battle to cure cancer. CAR T cell therapy is a powerful form of immunotherapy utilizing a patient's own immune cells which are reprogrammed and reintroduced into the patient's body to help destroy targeted tumor cells. New information regarding ongoing clinical trials is vital to practitioners to best treat their patients and stay abreast of leading edge treatment.
This educational program is directed toward allied healthcare professionals interested in the latest advances in the use of CAR T Cell therapy.
- Describe the mechanism of action for CAR T Cell Therapy.
- Identify the current indications of CAR T Cell Therapy.
- Recognize CAR T Cell Therapy treatment related toxicities and their management.
- Discuss the future direction of CAR T Cell Therapy.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Neal Prakash has indicated he has nothing to disclose.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
CAR T Cell Related Neurotoxicity has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this CAR T Cell Related Neurotoxicity- Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance